Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes

Overview

We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective

Detailed Description

Primary composite endpoints: Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine) Secondary endpoints: urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout

Interventions

  • Drug: pioglitazone

Participating in This Clinical Trial

Inclusion Criteria

  • type 2 diabetes HbA1c: more than 7% and less than 9% Exclusion Criteria:

  • insulin treatment

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Dokkyo Medical University
  • Overall Official(s)
    • Yoshimasa Aso, MD, Principal Investigator, Dokkyo Medical University, Koshigaya Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.